Multidrug-resistant Acinetobacter baumannii Pneumonia in Lung Transplant Recipients

• Published in: The Journal of heart and lung transplantation Vol. 27; no. 7; pp. 804 - 807
• Main Authors: Sopirala, Madhuri M., MD, Pope-Harman, Amy, MD, Nunley, David R., MD, Moffatt-Bruce, Susan, MD, PhD, Ross, Patrick, MD, PhD, Martin, Stanley I., MD
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01-07-2008; Elsevier Science
• Subjects: Acinetobacter baumannii; Acinetobacter Infections - drug therapy; Acinetobacter Infections - microbiology; Anti-Infective Agents - therapeutic use; Biological and medical sciences; Cardiology. Vascular system; Colistin - analogs & derivatives; Colistin - therapeutic use; Drug Resistance, Multiple, Bacterial; Female; Humans; Imipenem - therapeutic use; Lung Transplantation - adverse effects; Male; Medical sciences; Minocycline - analogs & derivatives; Minocycline - therapeutic use; Pneumonia - drug therapy; Pneumonia - microbiology; Risk Factors; Surgery; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the heart; Treatment Outcome; Lung disease; Pneumonia; Respiratory disease; Lung; Neisseriaceae; Transplantation; Homotransplantation; Phlebology; Acinetobacter baumannii; Treatment; Surgery; Multiple resistance; Bacteria; Graft; Micrococcales; Circulatory system; Cardiology
• ISSN: 1053-2498; 1557-3117
• DOI: 10.1016/j.healun.2008.03.023

We present 6 cases of multidrug-resistant (MDR) Acinetobacter baumannii pneumonia in lung transplant recipients. All cases were treated with imipenem and/or non-traditional antibiotics, such as tigecycline and colistimethate, and had different microbiologic and clinical outcomes. Prior treatment with broad-spectrum anti-microbial therapy was the single most likely risk factor for the development of infection due to MDR Acinetobacter baumannii . Ideal preventive and therapeutic strategies for this pathogen in lung transplant recipients require further study.